Table 1 Study patient demographics.
From: Dynamic contrast-enhanced magnetic resonance imaging for head and neck cancers
Patient Number | Sex | Age (years) | Race/Ethnicity | Smoking Status | Primary Tumor Site | TNM Category | AJCC Stage | Chemotherapy (weekly) |
|---|---|---|---|---|---|---|---|---|
1 | M | 52 | White | N | Base of tongue | T3N1M0 | III | Cisplatin |
2 | M | 53 | White | Y | Base of tongue | T2N2aM0 | IV | Cetuximab |
3 | M | 60 | White | Y | Tonsil | T4N2bM0 | IV | Cisplatin |
4 | M | 55 | White | Y | Tonsil | T3N2bM0 | IV | Cisplatin |
5 | M | 65 | White | N | Base of tongue | T2N1M0 | III | Cetuximab |
6 | M | 57 | Hispanic | Y | Tonsil | T2N2cM0 | IV | Cisplatin |
7 | M | 60 | White | Y | Base of tongue | T2N2bM0 | IV | Cisplatin |
8 | M | 58 | Black | Y | Base of tongue | T2N2cM0 | IV | Cisplatin |
9 | M | 62 | Asian | Y | Tonsil | T4N2cM0 | IV | Cisplatin |
10 | F | 48 | White | Y | Tonsil | T4N2bM0 | IV | Cisplatin |
11 | M | 56 | White | N | Tonsil | T2N2cM0 | IV | Cisplatin |
12 | M | 68 | White | Y | Tonsil | TxN2cM0 | IV | Cisplatin |
13 | M | 47 | White | N | Tonsil | T3N2bM0 | IV | Cisplatin |
14 | M | 47 | White | Y | Tonsil | T3N2bM0 | IV | Cisplatin |
15 | M | 55 | White | N | Base of tongue | T4N2bM0 | IV | Cisplatin |
